Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268200 | 0.84 | LMNA (0.49) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL880441 | 0.79 | MEN1 (0.69) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL880268 | 0.78 | LMNA (0.61) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6855803 | 0.77 | LMNA (0.54) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL18268182 | 0.77 | MEN1 (0.55) | LMNAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL12698524 | 0.77 | ALDH1A1 (0.83) | LMNAMAPK1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL880376 | 0.77 | ALDH1A1 (0.58) | LMNAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12698414 | 0.77 | ALDH1A1 (0.58) | LMNAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7156373 | 0.77 | ALDH1A1 (0.58) | LMNAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL10090757 | 0.76 | GAA (0.78) | MAPK1ALDH1A1KMT2ATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102567-B1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIV TENNESSEE RES FOUND (US) | 2019-07-17 | — | — | EP | disclosed |
| US-9834525-B2 | Inhibitors of paxillin function and related compositions and methods | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834525-B2 | Inhibitors of paxillin function and related compositions and methods | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | CTTN, PTK2, CDC42 | LMNA 797/4885MAPK1 1087/4885ALDH1A1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.